Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer ; volume:17 ; number:1 ; day:23 ; month:11 ; year:2017 ; pages:1-8 ; date:12.2017
BMC gastroenterology ; 17, Heft 1 (23.11.2017), 1-8, 12.2017
- Classification
-
Medizin, Gesundheit
- Creator
-
Kim, Dalyong
- Contributor
-
Kim, Sun Young
Lee, Ji Sung
Hong, Yong Sang
Kim, Jeong Eun
Kim, Kyu-Pyo
Kim, Jihun
Jang, Se Jin
Yoon, Young-Kwang
Kim, Tae Won
SpringerLink (Online service)
- DOI
-
10.1186/s12876-017-0694-6
- URN
-
urn:nbn:de:1111-201801253174
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kim, Dalyong
- Kim, Sun Young
- Lee, Ji Sung
- Hong, Yong Sang
- Kim, Jeong Eun
- Kim, Kyu-Pyo
- Kim, Jihun
- Jang, Se Jin
- Yoon, Young-Kwang
- Kim, Tae Won
- SpringerLink (Online service)
Other Objects (12)
![[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer](/assets/placeholder/searchResultMediaUnknown.png)
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
The relationship between oncogenic KRas and wild-type Ras activity and signaling
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
The relationship between oncogenic KRas and wild-type Ras activity and signaling
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy